|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价BTK抑制剂TM471-1胶囊在B细胞非霍奇金淋巴瘤(NHL)患者中的安全性、耐受性、药代动力学和初步药效的I期临床试验
[Translation] A Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BTK inhibitor TM471-1 capsules in patients with B-cell non-Hodgkin lymphoma (NHL)
剂量爬坡阶段:主要目的: (1)观察口服TM471-1胶囊单药在复发或难治B细胞NHL患者中的安全性和耐受性;(2)探索复发或难治B细胞NHL患者口服TM471-1胶囊单药的最大耐受剂量(maximal tolerated dose,MTD),II期推荐剂量(recommend phase 2 dose,RP2D)和剂量限制性毒性(dose-limiting toxicity,DLT)。次要目的:(1)评估TM471-1胶囊的药代动力学(pharmacokinetics,PK)特征;(2)评估TM471-1胶囊的药效学(pharmacodynamics,PD)特征; (3)初步观察TM471-1胶囊单药的抗肿瘤活性。
剂量扩展阶段:主要目的:评估TM471-1胶囊单药的有效性。次要目的:(1)评估TM471-1胶囊单药的安全性和耐受性;(2)探索TM471-1胶囊在脑脊液中的分布。
[Translation] Dose escalation phase: Primary objectives: (1) To observe the safety and tolerability of oral TM471-1 capsules alone in patients with relapsed or refractory B-cell NHL; (2) To explore the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D) and dose-limiting toxicity (DLT) of oral TM471-1 capsules alone in patients with relapsed or refractory B-cell NHL. Secondary objectives: (1) To evaluate the pharmacokinetic (PK) characteristics of TM471-1 capsules; (2) To evaluate the pharmacodynamic (PD) characteristics of TM471-1 capsules; (3) To preliminarily observe the anti-tumor activity of TM471-1 capsules alone.
Dose expansion phase: Primary objectives: To evaluate the efficacy of TM471-1 capsules alone. Secondary objectives: (1) to evaluate the safety and tolerability of TM471-1 capsules alone; (2) to explore the distribution of TM471-1 capsules in cerebrospinal fluid.
100 Clinical Results associated with Zhi Microbial Medicine (Xinxiang) Co., Ltd.
0 Patents (Medical) associated with Zhi Microbial Medicine (Xinxiang) Co., Ltd.
100 Deals associated with Zhi Microbial Medicine (Xinxiang) Co., Ltd.
100 Translational Medicine associated with Zhi Microbial Medicine (Xinxiang) Co., Ltd.